FSH is central to reproduction and regulates ovarian production of steroid hormones which in turn regulate endometrial growth/receptivity/regeneration/remodeling. However, these well defined boundaries of the 70s and 80s are now blurring with steroid hormone receptors being reported in the hematopoietic system and FSHR on several extragonadal sites including cancers in multiple tissues [1], and in the endometrium, myometrium, cervix, and placental [2] and hematopoietic system [3, 4]. Female patients being subjected to FSH therapy for stimulating their ovaries show effective mobilization of stem cells in their peripheral blood [5].

Bhartiya’s group reported that FSH treatment enhanced hematopoiesis in the bone marrow by almost 72 h in 5-FU treated mice [6]. How does FSH exerts its pleiotropic effects? What is the significance of FSHR3 and how significant it is functionally compared to the canonical FSHR1? Ovarian cancer cells do not exhibit cAMP signaling upon treatment with FSH [7].

Ratajczak and Bhartiya groups have published data to show FSHR expression on very-small embryonic-like stem cells (VSCLs) [4, 8] in reproductive tissues and surprisingly FSH treatment upregulated alternately spliced FSHR3 more significantly compared to the canonical FSHR1. Similarly, Sullivan et al. [9] reported FSHR3 to be the predominant isoform in sheep ovaries. It did not come as a surprise to see a special issue focused on different facets of FSH/FSHR biology published in 2020 wherein experts raised several concerns regarding extragonadal expression of FSHR [10]. They doubt the results and think these to be due to technical shortfalls [11].

Currently held belief written in golden letters in reproductive biology textbooks is the fact that initial follicle growth is gonadotropin independent and FSHR are not expressed on primordial follicles and that FSH acts on granulosa cells in the ovaries and Sertoli cells in the testes [12].

Bhartiya’s group points this as a ‘misconcept’ and points out this discrepancy has surfaced because of initial studies used only FSHR1 specific primers to detect FSHR in various types of follicles which will not detect FSHR3.

We are pleased to publish two review articles in the Journal of Ovarian Research on FSH/FSHR biology authored by Bhartiya’s group from ICMR-National Institute for Research in Reproductive Health, Mumbai, INDIA. The group has attempted to provide explanation to various concerns raised by Rahman’s group [11]. Since these articles question several basic existing paradigms in the field of reproductive biology including ovarian biology, further discussions and comments will be welcome and we will be pleased to publish in JOVR.